Latest Chemist Warehouse News

Sigma Healthcare has completed a reverse acquisition merger with Chemist Warehouse, reporting $6 billion in revenue and declaring a fully franked dividend. The merger reshapes Australia’s pharmacy landscape with ambitious synergy targets and operational shifts.

EBOS Group Limited reported solid FY25 results with 12% revenue growth and strategic acquisitions, setting sights on continued expansion and operational efficiency in FY26.

Tissue Repair Limited has secured major distribution partnerships in Australia, New Zealand, and Thailand for its TR Pro+® product line, marking a pivotal shift from development to commercialisation. The company is also scaling up manufacturing and advancing regulatory approvals to support its global expansion ambitions.

Cann Group Limited has reported a strong operational update, exceeding its medicinal cannabis production targets and significantly reducing costs, while expanding sales channels and securing fresh capital to bolster its balance sheet.

Sigma Healthcare has released its standalone annual and sustainability reports for the year ending January 2025, marking the final disclosures before its merger with Chemist Warehouse Group in February 2025.

Sigma Healthcare’s recent merger with Chemist Warehouse Group is delivering strong earnings growth, with Normalised EBIT rising 36% in the first half of FY25. Transaction costs remain significant but the combined group’s outlook appears robust.

Cann Group Limited reported a 20% rise in Q3 production and improved operating cash flow, while navigating a 38% sales dip due to order timing. The company bolstered its balance sheet with new funding and expanded its Botanitech distribution network.

Nuchev Limited reported a remarkable 215% increase in quarterly revenue, driven by the strategic launch of Oli6® in Vietnam and the acquisition of bWellness, signaling robust expansion across key Asia-Pacific markets.

EBOS Group Limited posted robust interim results for H1 FY25, with underlying EBITDA rising 7.1% excluding the Chemist Warehouse Australia contract, driven by strong organic growth and strategic investments. The company maintained its dividend and reiterated FY25 EBITDA guidance between $575 million and $600 million.

EBOS Group Limited posted a strong half-year performance with underlying EBITDA up 7.1% to $291 million, driven by growth in healthcare and animal care segments, while maintaining its interim dividend amid the loss of the Chemist Warehouse contract.

ASX Limited has reported a robust first half of FY25 with record operating revenue and a near 10% rise in underlying net profit, underpinned by strong growth across key business segments and a strategic focus on technology modernization.

Sigma Healthcare has completed its acquisition of Chemist Warehouse, issuing new shares and cash to former shareholders and appointing a refreshed board to steer the merged entity forward.